Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

61. Dabigatran (Pradaxa?): risk of serious haemorrhage

Dabigatran (Pradaxa?): risk of serious haemorrhage Dabigatran (Pradaxa▼): risk of serious haemorrhage Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Dabigatran (Pradaxa▼): risk of serious haemorrhage From: Therapeutic area: and Contraindications clarified and reminder to monitor renal function. Article date: July 2012 Dabigatran (Pradaxa▼) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation (...) . It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip replacement surgery or total knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day). Haemorrhage is a common adverse reaction with dabigatran. A review of world-wide data on the risk of bleeding with dabigatran, including results from clinical trials eg

MHRA Drug Safety Update2012

62. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Miller CS, Grandi SM, Shimony A, Filion (...) %. New oral anticoagulants investigated included apixaban, dabigatran and rivaroxaban. Varying proportions of patients had previously experienced stroke, transient ischaemic attack, heart failure, diabetes mellitus and/or hypertension at baseline. The authors did not report how many reviewers selected the studies for inclusion. Assessment of study quality The Cochrane Collaboration's tool was used to assess risk of bias as low, high or unclear for the following quality domains: Sequence generation

DARE.2012

63. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C CRD summary (...) All-cause deaths were equivalent for each treatment, but apixaban and dabigatran 110mg seemed to prevent more strokes, with least risk, for patients with non-valvular atrial fibrillation; dabigatran 150mg seemed better for patients at high risk of embolism. The review was generally poorly reported. The indirect comparisons and potential for confounding mean that the conclusions may not be reliable. Authors' objectives To compare the efficacy and safety of dabigatran, rivaroxaban, and apixaban

DARE.2012

64. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Kansal AR, Sharma M (...) , Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of dabigatran versus rivaroxaban as anticoagulation therapies for prevention

NHS Economic Evaluation Database.2012

65. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain

Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Gonzalez-Juanatey JR, Alvarez-Sabin J, Lobos JM, Martinez-Rubio A, Reverter JC, Oyaguez I, Gonzalez-Rojas N, Becerra V Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of dabigatran compared with warfarin and other prescribing patterns for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain. The authors concluded that dabigatran cost effective

NHS Economic Evaluation Database.2012

67. What role can dabigatran,rivaroxaban and apixaban play in the future?

What role can dabigatran,rivaroxaban and apixaban play in the future? Vol 19. DTB: Vol 19, No 3. May - July 2011 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB: Vol 19, No 3. May - July 2011 DTB: Vol 19, No 3. May - July 2011 Content tools Share it What role can dabigatran, rivaroxaban and apixaban play in the future? Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might

Drug and Therapeutics Bulletin of Navarre (Spain)2011

68. Acutely injured patients on dabigatran.

Acutely injured patients on dabigatran. Acutely injured patients on dabigatran. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22111735 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Nov 24;365(21):2039-40. doi: 10.1056/NEJMc1111095. Acutely injured patients on dabigatran. , , . Comment in [N Engl J Med. 2012] PMID: 22111735 DOI: [Indexed for MEDLINE] Free full text Publication type MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here

NEJM2011

69. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Shah SV, Gage BF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of treatments to prevent stroke in patients with atrial fibrillation. The authors concluded that dabigatran 150mg twice daily was cost-effective for populations at high risk of haemorrhage or stroke, unless the control of the international normalised ratio with warfarin was excellent. The methods were good and reported adequately, with the results reported in full. Given the scope of the analysis

NHS Economic Evaluation Database.2011

70. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery (...) Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Oslo: Norwegian Knowledge Centre

Health Technology Assessment (HTA) Database.2011

71. Dabigatran (Pradaxa) - For the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation

Dabigatran (Pradaxa) - For the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation

Scottish Medicines Consortium2011

72. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low- or high-dose dabigatran, compared with warfarin, for the prevention of ischaemic stroke in patients aged 65 years or older, with non-valvular atrial fibrillation and risk factors for stroke. The authors concluded that dabigatran, particularly at a high

NHS Economic Evaluation Database.2011

73. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison

Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Loke YK, Kwok CS CRD summary The authors concluded that oral anticoagulant rivaroxaban may be more effective than dabigatran for prevention (...) of venous thromboembolism after elective orthopaedic surgery, but that it might slightly increase the risk of haemorrhage. These conclusions reflect the evidence presented and are likely to be reliable. Authors' objectives To compare the efficacy and safety of dabigatran and rivaroxaban (oral anticoagulants) for prevention of venous thromboembolism after elective orthopaedic surgery. Searching PubMed (1950 onwards) and EMBASE (1980 onwards) were searched in May 2009. Search terms were reported

DARE.2011

74. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]

[Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L (...) . Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No 41. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and other issues related with coverage policies on the use of dabigatran and rivaroxaban as thrombophylaxis after a major orthopedic surgery. Authors

Health Technology Assessment (HTA) Database.2011

77. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial.

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. 21576658 2011 06 02 2011 08 02 2015 11 19 1524-4539 123 21 2011 May 31 Circulation Circulation Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant (...) therapy (RE-LY) trial. 2363-72 10.1161/CIRCULATIONAHA.110.004747 Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median

EvidenceUpdates2011

78. Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran.

Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File (...) 1 selected item: 21488759 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 May 12;364(19):1788-90. doi: 10.1056/NEJMp1103050. Epub 2011 Apr 13. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. 1 , , . 1 Division of Cardiovascular and Renal Products, Office of New Drugs, Center

NEJM2011

79. [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation]

[Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation] Dabigatrán en la prevención del accidente cerebrovascular isquémico en pacientes con fibrilación auricular [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation] Dabigatrán en la prevención del accidente cerebrovascular isquémico en pacientes con fibrilación auricular [Dabigatran for the prevention of ischemic stroke in patients with acute (...) cerebrovascular isquémico en pacientes con fibrilación auricular. [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°249. 2011 Authors' objectives The purpose of this report is to assess the evidence available on the efficacy, safety and issues related to coverage policies on the use of dabigatran for the prevention of ischemic stroke (IS) in patients

Health Technology Assessment (HTA) Database.2011

80. [Dabigatran to prevent stroke in patients with atrial fibrillation]

[Dabigatran to prevent stroke in patients with atrial fibrillation] Dabigatran för att förebygga stroke vid förmaksflimmer [Dabigatran to prevent stroke in patients with atrial fibrillation] Dabigatran för att förebygga stroke vid förmaksflimmer [Dabigatran to prevent stroke in patients with atrial fibrillation] SBU Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation SBU. Dabigatran för att förebygga stroke vid förmaksflimmer. [Dabigatran to prevent stroke in patients with atrial fibrillation] Stockholm: The Swedish Council on Health Technology Assessment (SBU). SBU Alert 2011-04. 2011 Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Atrial Fibrillations; Benzimidazoles; Pyridines; Stroke Language Published Swedish Country of organisation Sweden English summary An English language summary

Health Technology Assessment (HTA) Database.2011